A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

Inclusion Criteria: * Confirmed diagnosis of PMN with positive anti-PLA2R antibodies * CD19+ B cell count ≥40 cells/μL * UPCR ≥2.0 g/g * eGFR ≥35 mL/min/1.73 m² * Stable RAAS inhibitor therapy * Blood pressure \<150/90 mmHg at baseline * Adequate hematologic, hepatic, and renal function * Willing to use effective contraception (both sexes) * Other inclusion criteria may apply Exclusion Criteria: * Secondary Membranous Nephropathy * Rapidly progressive glomerulonephritis or other glomerulopathies * Prior B cell-depleting therapy within 24 weeks * Recent use of immunosuppressants * Active or high-risk infections * History of malignancy * Pregnancy or breastfeeding * Recent major surgery or hospitalization * Other exclusion criteria may apply